APA (7th ed.) Citation

E, B., JP, S., V, J., M, B., AK, W., R, L., . . . I, J. (2023). Combined proteomics and CRISPR‒Cas9 screens in PDX identify ADAM10 as essential for leukemia in vivo. Molecular cancer, 22(1), 107. https://doi.org/10.1186/s12943-023-01803-0

Chicago Style (17th ed.) Citation

E, Bahrami, et al. "Combined Proteomics and CRISPR‒Cas9 Screens in PDX Identify ADAM10 as Essential for Leukemia in Vivo." Molecular Cancer 22, no. 1 (2023): 107. https://doi.org/10.1186/s12943-023-01803-0.

MLA (9th ed.) Citation

E, Bahrami, et al. "Combined Proteomics and CRISPR‒Cas9 Screens in PDX Identify ADAM10 as Essential for Leukemia in Vivo." Molecular Cancer, vol. 22, no. 1, 2023, p. 107, https://doi.org/10.1186/s12943-023-01803-0.